You are here: Industry Insights > cannabinoid

News List

Cannabics Pharmaceuticals and Purisys sign cannabinoid API supply agreement CPhIonline
November 08, 2021
Purisys has agreed to supply Cannabics Pharmaceuticals, a global developer of cancer-related cannabinoid-based medicine, with GMP-grade APIs required for the manufacturing of its colorectal cancer treatment drug candidate.
InMed, Almac Improving Cannabinoid Production Methods contractpharma
May 11, 2020
InMed Pharmaceuticals and the Almac Group have partnered on a proprietary approach to augment current biosynthesis-based methods for cannabinoid production.
Interest in Marijuana, Cannabinoids for Pain Rising Rapidly drugs
September 02, 2019
There is rapidly growing interest in the use of marijuana and cannabinoids for pain, according to a survey commissioned by the American Society of Anesthesiologists (ASA).
Cannabinoid topical cream for treatment of Female Hypoactive Sexual Desire Disorder europeanpharmaceuticalreview
April 22, 2019
Pivot Pharmaceuticals Inc. is to begin human clinical trials of PVT-005, the pharmaceutical drug candidate for the treatment of HSDD…
Go for a run or eat chocolate: A choice dictated by the cannabinoid receptors worldpharmanews
March 20, 2019
Physical inactivity is a common factor in lifestyle diseases - and one that is often linked to the excessive consumption of fatty and/or sugary foods.
Therapix Biosciences Terminates FSD Acquisition Letter of Intent americanpharmaceuticalreview
December 24, 2018
Therapix Biosciences, a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments.....
OWC Reports Progress in Clinical Trials for Ointment Care for Skin Diseases americanpharmaceuticalreview
December 03, 2018
OWC Pharmaceutical, a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, reported the last healthy.....
InMed Files Patent Application for its Cannabinoid Biosynthesis Program americanpharmaceuticalreview
September 11, 2018
InMed has filed a Patent Cooperation Treaty (PCT) application pertaining to the company's proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature.
FDA advisors back approval of GW’s Epidiolex pharmatimes
July 16, 2018
As expected, an FDA advisory panel has backed approval of GW Pharmaceuticals/Greenwich Bioscience’s Epidiolex for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
NEJM publishes second successful Epidiolex trial in LGS pharmatimes
July 12, 2018
The New England Journal of Medicine has published the second of two late stage studies showing that GW Pharma’s cannabinoid Epidiolex cut seizures in patients with the rare childhood epilepsy Lennox-Gastaut Syndrome.